Repositioning Candidate Details
| Candidate ID: | R0888 |
| Source ID: | DB05866 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | ETC-1001 |
| Synonyms: | -- |
| Molecular Formula: | -- |
| SMILES: | -- |
| DrugBank Description: | ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders. |
| CAS Number: | -- |
| Molecular Weight: | |
| DrugBank Indication: | Investigated for use/treatment in hyperlipidemia. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | ETC-1001 is a synthetic, orally-active lipid regulating agent designed to elevate levels of high-density lipoprotein cholesterol (HDL-C), the "good" cholesterol. In pre-clinical studies, it shows the ability to elevate HDL-cholesterol levels, while also reducing levels of low-density lipoprotein cholesterol (LDL-C), the "bad" cholesterol, and triglycerides. It also inhibits the progression of atherosclerosis in pre- clinical models. |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I07 | 1936 | Arteriosclerosis | Build-up of fatty material and calcium deposition in the arterial wall resulting in partial or complete occlusion of the arterial lumen.https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&ns=ncit&code=C35768 | disease of anatomical entity/cardiovascular system disease/ vascular disease/ artery disease | Details |